The novel immunotherapeutic oligodeoxynucleotide imt504 protects neutropenic animals from fatal pseudomonas aeruginosa bacteremia and sepsis

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 2, 2015, Pages 1225-1229

  Chahin, Abdullah ^a   Opal, Steven M ^a   Zorzopulos, Jorge ^b   Jobes, David V ^c   Migdady, Yazan ^a   Yamamoto, Michelle ^a   Parejo, Nicholas ^a   Palardy, John E ^a   Horn, David L ^c,d  

^a MEMORIAL HOSPITAL OF RHODE ISLAND   (United States)

^b Immunotech SA and Bioadvisory SA Buenos Aires ^*  (Argentina)

^c Mid Atlantic BioTherapeutics   (United States)

^d David Horn LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFEPIME; CYCLOPHOSPHAMIDE; IMMUNOMODULATING AGENT; IMT 504; INTERLEUKIN 6; OLIGODEOXYNUCLEOTIDE DERIVATIVE; UNCLASSIFIED DRUG; IMT504; OLIGODEOXYRIBONUCLEOTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; BACTERIAL COLONIZATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; FATALITY; FEVER; GRAM NEGATIVE INFECTION; IMMUNOTHERAPY; MONOTHERAPY; MOUSE; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RAT; SEPSIS; SURVIVAL; ANIMAL; DRUG EFFECTS; FEMALE; MICROBIOLOGY; PATHOGENICITY;

ANIMALS; BACTEREMIA; FEMALE; NEUTROPENIA; OLIGODEOXYRIBONUCLEOTIDES; PSEUDOMONAS AERUGINOSA; RATS; SEPSIS;

EID: 84921902541     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03923-14     Document Type: Article

References (31)

1. Dellinger P, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb SA, Beale RJ, Vincent JL, Moreno R, Surviving Sepsis Campaign Guidelines Committee including the Pediatric Subgroup. 2013. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 41:580-637. http://dx.doi.org/10.1097/CCM .0b013e31827e83af.
2. ProCESS Investigators, Yealy DM, Kellum JA, Huang DT, Barnato AE, Weissfeld LA, Pike F, Terndrup T, Wang HE, Hou PC, LoVecchio F, Filbin MR, Shapiro NI, Angus DC. 2014. A randomized trial of protocolbased care for early septic shock. N Engl J Med 370:1683-1693. http://dx .doi.org/10.1056/NEJMoa1401602.
3. Hotchkiss RS, Opal S. 2010. Immunotherapy for sepsis - a new approach against an ancient foe.NEngl J Med 363:87-89. http://dx.doi.org/10.1056 /NEJMcibr1004371.
4. Vincent J-L, Opal SM, Marshall J, Tracey K. 2013. Definitions for sepsis: time for a change. Lancet 381:774-775. http://dx.doi.org/10.1016/S0140 -6736(12)61815-7.
5. Opal SM, Dellinger RP, Vincent JL, Angus D, Masur H. 2014. The next generation of sepsis trials: a critical reassessment after the demise of human recombinant activated protein C. Crit Care Med 42:1714-1721. http: //dx.doi.org/10.1097/CCM.0000000000000325.
6. Cavaillon JM, Eisen D, Annane D. 2014. Is boosting the immune system in sepsis appropriate? Crit Care 18: 216. http://dx.doi.org/10.1186/cc13787.
7. Jin JO, Yu Q. 2013. Systemic administration of TLR3 agonist induces IL-7 expression and IL-7-dependent CXCR3 ligand production in the lung. J Leukoc Biol 93:413-425. http://dx.doi.org/10.1189/jlb.0712360.
8. Brahmamdam P, Inoue S, Unsinger J, Chang KC, McDunn JE, Hotchkiss RS. 2010. Delayed administration of anti-PD1 antibody reverses immune dysfunction and improves survival during sepsis. J Leukoc Biol 88:233-240. http://dx.doi.org/10.1189/jlb.0110037.
9. Shubin NJ, Monaghan SF, Hefferman DS, Chung CS, Ayala A. 2013. B and T lymphocyte attenuator expression on CD4+ T cells associates with sepsis and subsequent infections in ICU patients. Crit Care 17:R276. http: //dx.doi.org/10.1186/cc13131.
10. Laxminarayan R, Duse A, Wattal C, Zaidi AK, Wertheim HF, Sumpradit N, Vlieghe E, Hara GL, Gould IM, Goossens H, Greko C, So AD, Bigdeli M, Tomson G, Woodhouse W, Ombaka E, Peralta AQ, Qamar FN, Mir F, Kariuki S, Bhutta ZA, Coates A, Bergstrom R, Wright GD, Brown ED, Cars O. 2013. Antibiotic resistance-the need for global solutions. Lancet Infect Dis 13:1057-1098. http://dx.doi.org/10.1016 /S1473-3099(13)70318-9.
11. Camp C, Tatum OL. 2010. A review of Acinetobacter baumannii as a highly successful pathogen in times of war. Lab Med 41:649-657. http: //dx.doi.org/10.1309/LM90IJNDDDWRI3RE.
12. Arnold RS, Thom KA, Sharma S, Phillips M, Johnson JK, Morgan DJ. 2011. Emergence of Klebsiella pneumoniae carbapenemase (KPC)-producing bacteria. South Med J 104:40-45. http://dx.doi.org/10.1097 /SMJ.0b013e3181fd7d5a.
13. Elias F, Flo J, Lopez RA, Zorzopulos J, Montaner A, Rodriguez JM. 2003. Strong cytosine-guanosine-independent immunostimulation in humans and other primates by synthetic oligodeoxynucleotides with PyNTTTTGT motifs. J Immunol 171:3697-3704. http://dx.doi.org/10 .4049/jimmunol.171.7.3697.
14. Montaner AD, Denichilo A, Rodriguez JM, Flo J, Lopez RA, Pontoriero A, Savy V, Baumeister E, Frant R, Zorzopulos J, Elias F. 2011. Addition of the immunostimulatory oligonucleotide IMT504 to a seasonal flu vaccine increases hemagglutinin antibody titers in young adult and elder rats, and expands the anti-hemagglutinin antibody repertoire. Nucleic Acid Ther 21:265-274. http://dx.doi.org/10.1089/nat.2011.0284.
15. Rodriguez JM, Elias F, Montaner A, Flo J, Lopez RA, Zorzopulos J, Franco RJ, Lenial SP, Lopez Salón M, Pirpignani ML, Solimano J, Garay G, Riveros D, Fernandez J, Cacchione R, Dupont J. 2006. ODN IMT504 induces an immunogenic phenotype and apoptosis of chronic lymphocytic leukemia cells. Medicina (B Aires) 66:9-16.
16. Hernando Insúa A, Montaner AD, Rodriguez JM, Elías F, Fló J, López RA, Zorzopulos J, Hofer EL, Chasseing NA. 2007. IMT504, the prototype of the immunostimulatory oligonucleotides of the PyNTTTTGT class, increases the number of progenitors of mesenchymal stem cells both in vitro and in vivo: potential use in tissue repair therapy. Stem Cells 25:1047-1054. http://dx.doi.org/10.1634/stemcells.2006-0479.
17. Franco R, Rodriquez JM, Elias F, Hernando-Insua A, Flo J, Lopez R, Nagle L, Zorzopulos J, Horn DL, Montaner AD. 10 April 2014, posting date. Non-clinical safety studies of IMT504, a unique non-CpG oligonucleotide. Nucleic Acid Ther http://dx.doi.org/10.1089/nat.2013.0479.
18. Hernando-Insúa A, Rodriguez JM, Elías F, Fló J, López R, Franco R, Lago N, Zorzopulos J, Montaner AD. 2010. A high dose of IMT504, the PyTTTTGT prototype immunostimulatory oligonucleotide, does not alter embryonic development in rats. Oligonucleotides 20:33-36. http://dx .doi.org/10.1089/oli.2009.0206.
19. Krieg AM. 2002. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 20:709-760. http://dx.doi.org/10.1146/annurev .immunol.20.100301.064842.
20. Opal SM, Palardy JE, Chen W, Parejo N, Bhattacharjee A, Cross A. 2005. Active immunization with a detoxified endotoxin vaccine protects against lethal polymicrobial sepsis: its use with CpG adjuvant and potential mechanisms. J Infect Dis 192:2074-2080. http://dx.doi.org/10.1086 /498167.
21. Yigit H, Queenan AM, Anderson GJ, Domenech-Sanchez A, Biddle JW, Steward CD, Alberti S, Bush K, Tenover FC. 2001. Novel carbapenemhydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother 45:1151-1161. http://dx.doi.org/10.1128/AAC.45.4.1151-1161.2001.
22. Marchaim D, Chopra T, Pogue JM, Perez F, Hujer AM, Rudin S, Endimiani A, Navon-Venezia S, Hothi J, Slim J, Blunden C, Shango M, Lephart PR, Salimnia H, Reid D, Moshos J, Hafeez W, Bheemreddy S, Chen TY, Dhar S, Bonomo RA, Kaye KS. 2011. Outbreak of colistinresistant, carbapenem-resistant Klebsiella pneumoniae in metropolitan Detroit, Michigan. Antimicrob Agents Chemother 55:593-599. http://dx .doi.org/10.1128/AAC.01020-10.
23. Wang S-J, Chiu S-H, Lin Y-C, Tsai Y-C, Mu J-J. 2013. Carbapenem resistant enterobacteriaceae carrying New Delhi metallo-ß-lactamase gene (NDM-1) in Taiwan. Diagn Microbiol Infect Dis 76:248-249. http: //dx.doi.org/10.1016/j.diagmicrobio.2013.02.003.
24. Dimou V, Dhanji H, Pike R, Livermore DM, Woodford N. 2012. Characterization of Enterobacteriaceae producing OXA-48-like carbapenemases in the UK. J Antimicrob Chemother 67:1660-1665. http://dx .doi.org/10.1093/jac/dks124.
25. Gea-Banacloche JC, Opal SM, Jorgensen J, Carcillo JA, Sepkowitz KA, Cordonnier C. 2004. Sepsis associated with immunosuppressive medications: an evidence-based review. Crit Care Med 32:S578-S590. http://dx .doi.org/10.1097/01.CCM.0000143020.27340.FF.
26. Hack CE, De Groot ER, Felt-Bersma RJ, Nuijens JH, Strack Van Schijndel RJ, Eerenberg-Belmer AJ, Thijs LG, Aarden LA. 1989. Increased plasma levels of interleukin-6 in sepsis. Blood 74:1704-1710.
27. Weber GF, Chousterman BG, Hilgendorf I, Robbins CS, Theurl I, Gerhardt LM, Iwamoto Y, Quach TD, Ali M, Chen JW, Rothstein TL, Nahrendorf M, Weissleder R, Swirski FK. 2014. Pleural innate response activator B cells protect against pneumonia via a GM-CSF-IgM axis. J Exp Med 211:1243-1256. http://dx.doi.org/10.1084/jem.20131471.
28. Subramaniam R, Barnes PF, Fletcher K, Boggaram V, Hillberry Z, Neuenschwander P, Shams H. 2014. Protecting against post-influenza bacterial pneumonia by increasing phagocyte recruitment and ROS production. J Infect Dis 209:1827-1836. http://dx.doi.org/10.1093/infdis /jit830.
29. Karczmarczyk M, Martins M, Quinn T, Leonard N, Fanning S. 2011. Mechanisms of fluoroquinolone resistance in Escherichia coli isolates from food-producing animals. Appl Environ Microbiol 77:7113-7120. http: //dx.doi.org/10.1128/AEM.00600-11.
30. Ramalhete C, Spengler G, Martins A, Martins M, Viveiros M, Mulhovo S, Ferreira MJ, Amaral L. 2011. Inhibition of efflux pumps in methicillinresistant Staphylococcus aureus and Enterococcus faecalis resistant strains with triterpenoids from Momordica balsamina. Int J Antimicrob Agents 37:70-74. http://dx.doi.org/10.1016/j.ijantimicag.2010.09.011.
31. Høiby N. 2011. Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis. BMC Med 9:32. http://dx.doi.org/10 .1186/1741-7015-9-32.